Xinjiang Tianshan Animal Husbandry Bio-engineering Past Earnings Performance
Past criteria checks 0/6
Xinjiang Tianshan Animal Husbandry Bio-engineering has been growing earnings at an average annual rate of 5.2%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 14.4% per year.
Key information
5.2%
Earnings growth rate
4.7%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -14.4% |
| Return on equity | -157.4% |
| Net Margin | -38.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. (SZSE:300313) Investors Are Less Pessimistic Than Expected
Oct 02
Some Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. (SZSE:300313) Shareholders Look For Exit As Shares Take 26% Pounding
Jun 27Some Confidence Is Lacking In Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. (SZSE:300313) As Shares Slide 35%
Apr 19What Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd.'s (SZSE:300313) 44% Share Price Gain Is Not Telling You
Mar 05Revenue & Expenses Breakdown
How Xinjiang Tianshan Animal Husbandry Bio-engineering makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 132 | -51 | 30 | 2 |
| 30 Jun 24 | 138 | -37 | 29 | 1 |
| 31 Mar 24 | 132 | -25 | 28 | 2 |
| 31 Dec 23 | 137 | -22 | 27 | 2 |
| 30 Sep 23 | 142 | -17 | 21 | 1 |
| 30 Jun 23 | 94 | -33 | 19 | 1 |
| 31 Mar 23 | 87 | -31 | 18 | 0 |
| 01 Jan 23 | 76 | -32 | 18 | 1 |
| 30 Sep 22 | 93 | -34 | 21 | 2 |
| 30 Jun 22 | 96 | -29 | 22 | 2 |
| 31 Mar 22 | 110 | -30 | 23 | 2 |
| 01 Jan 22 | 108 | -27 | 27 | 2 |
| 30 Sep 21 | 91 | -14 | 25 | 0 |
| 30 Jun 21 | 94 | 2 | 28 | 0 |
| 31 Mar 21 | 135 | 7 | 30 | 0 |
| 31 Dec 20 | 163 | 4 | 30 | 1 |
| 30 Sep 20 | 282 | -36 | 48 | 2 |
| 30 Jun 20 | 277 | -50 | 52 | 2 |
| 31 Mar 20 | 239 | -57 | 55 | 2 |
| 31 Dec 19 | 229 | -61 | 58 | 2 |
| 30 Sep 19 | 116 | -51 | 51 | 2 |
| 30 Jun 19 | 121 | -104 | 51 | 1 |
| 31 Mar 19 | 107 | -1,949 | 53 | 1 |
| 31 Dec 18 | 105 | -1,946 | 51 | 1 |
| 30 Sep 18 | 125 | -1,919 | 49 | 2 |
| 30 Jun 18 | 162 | -1,855 | 49 | 2 |
| 31 Mar 18 | 192 | 7 | 49 | 2 |
| 31 Dec 17 | 195 | 7 | 51 | 2 |
| 30 Sep 17 | 181 | -78 | 73 | 1 |
| 30 Jun 17 | 245 | -108 | 84 | 0 |
| 31 Mar 17 | 272 | -128 | 90 | 0 |
| 31 Dec 16 | 375 | -140 | 97 | 0 |
| 30 Sep 16 | 419 | -79 | 88 | 0 |
| 30 Jun 16 | 407 | -55 | 82 | 0 |
| 31 Mar 16 | 362 | -44 | 80 | 0 |
| 31 Dec 15 | 247 | -36 | 74 | 0 |
| 30 Sep 15 | 214 | -19 | 64 | 0 |
| 30 Jun 15 | 129 | -13 | 58 | 0 |
| 31 Mar 15 | 125 | -6 | 52 | 0 |
| 31 Dec 14 | 122 | 2 | 46 | 0 |
| 30 Sep 14 | 95 | 8 | 37 | 0 |
| 30 Jun 14 | 88 | 10 | 36 | 0 |
| 31 Mar 14 | 84 | 12 | 33 | 0 |
| 31 Dec 13 | 83 | 10 | 34 | 0 |
Quality Earnings: 300313 is currently unprofitable.
Growing Profit Margin: 300313 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300313 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.2% per year.
Accelerating Growth: Unable to compare 300313's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300313 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).
Return on Equity
High ROE: 300313 has a negative Return on Equity (-157.42%), as it is currently unprofitable.